PTC Therapeutics (PTCT) announced on Monday that its Sephience drug has been approved by the Japanese Ministry of Health, Labor, and Welfare for the treatment of children and adults with phenylketonuria.
The company stated that it is in pricing discussions, which are expected to conclude in Q1 2026, and the launch is anticipated to follow shortly thereafter.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments